Market Overview

UPDATE: Maxim Group Cuts PT to $24 on ARIAD Pharmaceuticals; Label Warning Reduces Forecast

Share:
Related ARIA
The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors
Ariad Announces FDA Has Given Clearance To Begin Clinical Development Trial

Maxim Group reiterated its Buy rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) and a $24 price target.

Maxim Group said, "Unexpectedly, Iclusig's label contains a boxed warning on arterial thrombosis and hepatotoxicity. … The information suggests (1) Iclusig may have an disadvantage in competing against other CML drugs and (2) if physicians reduce dose to 15mg/day because of adverse events, Iclusig may generate smaller sales… We are reducing our peak penetration assumption to 22% from 30% to reflect potential hurdles for doctors to prescribe Iclusig. However, lower penetration is partially offset by higher-thanexpected selling price."

ARIAD Pharmaceuticals closed at $18.93 on Friday.

Latest Ratings for ARIA

DateFirmActionFromTo
Jan 2016BarclaysInitiates Coverage onUnderweight
Dec 2014Credit SuisseDowngradesNeutralUnderperform
Aug 2014CitigroupMaintainsSell

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Maxim GroupAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (ARIA)

Get Benzinga's Newsletters